Synthetic organic

LBM-415.

LBM-415.

Lck Inhibitor is a cell-permeable pyrrolopyrimidine compound that acts as a potent, selective, and ATP-competitive inhibitor of Lck (IC|50|at 5 μM ATP = &lt: 1 nM, 2 nM, 70 nM, 1.57 μM and 1.98 μM for lck|64-509|Y|39|4, Lckcd pY394, Src, Kdr and

LCL 161, phenol.

LCL161, a SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). Phase 2.

LCL161, a SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). Phase 2.

LCL161, a SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). Phase 2.

LCL161, a SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). Phase 2.

LCQ-908.

LCQ-908.

LCQ-908.

InformationLDC1267 LDC1267 is a highly selective TAM kinase inhibitor with IC50 of &lt:5 nM, 8 nM, and 29 nM for Mer, Tyro3, and Axl, respectively. Displays lower activity against Met, Aurora B, Lck, Src, and CDK8.TargetsMer (Cell-free assay): Tyro3